SCHEMBL142926

SCHEMBL142926

O=c1ccc(C(F)(F)F)cn1-c1ccc(O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.47
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
NFKB1 P19838 1/20 0.42
RAB9A P51151 1/20 0.42
GFER P55789 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
RCE1 Q9Y256 1/20 0.42
ME2 P23368 1/20 0.40
ME1 P48163 1/20 0.40
ME3 Q16798 1/20 0.40
ESR1 P03372 2/20 0.39
ESR2 Q92731 2/20 0.39
USP7 Q93009 1/20 0.39
PTGS2 P35354 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12333052 0.89 GSK3A (0.42) KDM4EALDH1A1HPGDTDP1CYP1A2
SCHEMBL142716 0.84 NPC1 (0.46) KDM4EALDH1A1HPGDNPC1RAB9A
SCHEMBL10079688 0.83 RORC (0.43) SMN1; SMN2
SCHEMBL10079418 0.82 KDM4E (0.37) KDM4EALDH1A1HPGDNPC1POLB
SCHEMBL13075264 0.82 ALDH1A1 (0.41) KDM4EALDH1A1HPGDTDP1CYP1A2
SCHEMBL29348797 0.82 KDM4E (0.42) KDM4EALDH1A1HPGDPOLBTDP1
SCHEMBL10305669 0.82 ALDH1A1 (0.53) KDM4EALDH1A1HPGDPTGS2PTGS1
SCHEMBL6116854 0.82 KIF11 (0.47) KIF11KDM4EALDH1A1HPGDPTGS1
SCHEMBL141047 0.82 MIF (0.46) KDM4EALDH1A1HPGDSMN1; SMN2PTGS2
SCHEMBL143208 0.81 ALDH1A1 (0.56) KIF11KDM4EALDH1A1HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10010536-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2018-07-03 US disclosed
US-10010536-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2018-07-03 US disclosed
US-10010536-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2018-07-03 US disclosed
US-20170095462-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. 2017-04-06 US disclosed
US-20170095462-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. 2017-04-06 US disclosed
US-20170095462-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. 2017-04-06 US disclosed
US-9527816-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2016-12-27 US disclosed
US-9527816-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2016-12-27 US disclosed
US-9527816-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2016-12-27 US disclosed
EP-2591784-B1 Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system INTERMUNE INC (US) 2016-09-14 EP disclosed
US-7728013-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2010-06-01 US disclosed
US-7728013-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2010-06-01 US disclosed
US-7728013-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2010-06-01 US disclosed
US-20100029578-A1 Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds INTERMUNE, INC. 2010-02-04 US disclosed
US-20100029578-A1 Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds INTERMUNE, INC. 2010-02-04 US disclosed
CN-101237869-A Pyridone derivatives for modulating stress-activated protein kinase system INTERMUNE INC (US) 2008-08-06 CN disclosed
WO-2007062167-A9 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE INC (US) 2007-07-26 WO disclosed
WO-2007062167-A2 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. (US) 2007-05-31 WO disclosed
WO-2007053685-A2 METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS INTERMUNE, INC. (US) 2007-05-10 WO disclosed
US-20060270612-A1 Method of modulating stress-activated protein kinase system INTERMUNE, INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029578-A1 Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds ATF1, MAPKAPK3, MAPKAPK2 KIF11 2980/4885KDM4E 4212/4885ALDH1A1 900/4885
US-10010536-B2 Method of modulating stress-activated protein kinase system MAPKAPK2, MAP3K6, MAP4K1 KIF11 3245/4885KDM4E 3655/4885ALDH1A1 3375/4885
US-20170095462-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM MAPKAPK2, MAP3K6, MAP4K1 KIF11 3245/4885KDM4E 3655/4885ALDH1A1 3375/4885
US-20060270612-A1 Method of modulating stress-activated protein kinase system MAPKAPK2, MAP3K6, MAP4K1 KIF11 3245/4885KDM4E 3655/4885ALDH1A1 3375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.